<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168062</url>
  </required_header>
  <id_info>
    <org_study_id>135513</org_study_id>
    <secondary_id>NCI-2015-01058</secondary_id>
    <nct_id>NCT02168062</nct_id>
  </id_info>
  <brief_title>Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer</brief_title>
  <official_title>A Multidisciplinary Team-Based Approach to Mitigate the Impact of Androgen Deprivation Therapy in Prostate Cancer: A Randomized Phase 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot partially-randomized phase II trial studies how well Supportive Therapy in
      Androgen Deprivation (STAND) clinic works in improving health outcomes and managing side
      effects in patients with prostate cancer. Individualized counseling regarding exercise and
      dietary habits may help improve patient understanding, satisfaction, and overall lessen
      adverse impact on quality of life caused by androgen deprivation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the mean percent change from baseline to 12 months in percentage body fat mass
      among men with prostate cancer receiving androgen deprivation therapy randomized to
      participate in the ?STAND? clinic versus (vs.) usual standard of care. (Randomized Cohort)
      II. To determine the feasibility of completing multi-disciplinary STAND clinic visits within
      context of concurrent chemohormonal therapy for prostate cancer. (Non-randomized Pilot
      Cohort)

      SECONDARY OBJECTIVES:

      I. To compare the mean percent change from baseline to 12 months and patterns of change over
      time during participation in the STAND clinic vs. usual standard of care with respect to:
      metabolic impact on diabetes and cardiovascular risk factors, bone health, and quality of
      life/psychosocial impact.

      II. Among men randomized to receive usual standard of care that cross-over to participate in
      the STAND clinic after month 12 of the study: to measure the mean change from baseline at
      start of participation in the STAND clinic after 12 months of participation in: metabolic
      parameters including percentage body fat, fasting insulin/glucose, homeostatic model
      assessment insulin resistance (HOMA-IR), body weight/body mass index, waist circumference;
      bone health; quality of life; and patient satisfaction.

      III. Among men in the non-randomized pilot cohort: to determine the mean change from baseline
      to 12 months during STAND clinic participation in the primary and secondary metabolic and
      quality of life parameters listed above.

      TERTIARY OBJECTIVES:

      I. To investigate for a relationship between inherited genetic polymorphisms of functional
      relevance near or within genes encoding proteins with roles in steroid hormone transport and
      androgen receptor signaling with changes in metabolic parameters among men treated with
      androgen deprivation therapy.

      II. To investigate changes in trabecular bone micro-architecture as measured by high
      resolution peripheral quantitative computed tomography (QCT) Imaging of radius and tibia
      during androgen deprivation therapy.

      III. To investigate for relationship between 2nd digit to 4th digit length ratio (2D:4D
      ratio) and quality of life on androgen deprivation therapy.

      IV. To investigate for a relationship between 2nd digit to 4th digit length ratio and
      baseline empathy score as measured by validated questionnaire.

      OUTLINE: Patients receiving androgen deprivation therapy are randomized to 1 of 2 arms and
      patients receiving concurrent chemohormonal therapy are assigned to Arm II.

      ARM I (STANDARD OF CARE): Patients receive leuprolide acetate subcutaneously (SC) or
      intramuscularly (IM), goserelin acetate SC, or triptorelin pamoate IM and visit their health
      care provider every 3 months for 12 months. Patients will be referred to a nutrition,
      exercise, and symptom management service upon patient request or if deemed necessary by a
      healthcare provider. Patients may cross-over to Arm II after 12 months.

      ARM II (STAND CLINIC): Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or
      triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules
      discussing various aspects of anti-androgen therapy and management of side effects and meet
      one-to-one with a licensed exercise trainer, registered dietician, and symptom management
      service to receive individualized counseling monthly for 12 months.

      After completion of study treatment, patients are followed up at 2, 4, and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding
  </why_stopped>
  <start_date type="Actual">June 16, 2014</start_date>
  <completion_date type="Actual">May 22, 2018</completion_date>
  <primary_completion_date type="Actual">May 22, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change in Percentage Body Fat Mass as Measured by Bioelectrical Impedance Analyzer (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The absolute change from baseline in percentage body fat after 12 months of study participation for participants in the randomized cohort was measured using a bioelectrical impedance analyzer and between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in the Non-randomized, Pilot, Cohort Who Completed Clinic Visits</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The percentage of participants in the pilot, non-randomized cohort who completed clinic visits for Supportive Therapy in Androgen Deprivation (STAND) will be reported to assess feasibility.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Blood Pressure (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in systolic and diastolic blood pressure from the baseline to month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Body Weight (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in body weight from the baseline to month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Percentage of Body Fat (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in percentage of body fat from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Waist Circumference (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in waist circumference from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Hemoglobin A1c (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in percentage hemoglobin A1c from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Insulin Resistance Score (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in insulin resistance scores from the baseline to the month 12 assessment. Insulin resistance scores were calculated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). This calculation marks for both the presence and extent of any insulin resistance that participants might currently express. The HOMA-IR is an assessment using insulin and glucose lab values to generate an insulin resistance score. A healthy score range is 1.0 (0.5-1.4). A score of less than 1.0 means you are insulin-sensitive which is optimal. A score above 1.9 indicates early insulin resistance. A score above 2.9 indicates significant insulin resistance. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Fasting Lipids (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in fasting lipids which includes total cholesterol, low density lipoprotein, High density lipoprotein, and triglycerides levels from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Hours Per Week of Physical Activity Category as Measured by the Exercise Pattern Assessment (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Metabolic impact for participants from baseline to 12 months was measured using an exercise pattern questionnaire. The questionnaire measured self-reported average total time per week over the past year the participant participated in various physical activities such as walking, tennis, yoga, swimming, etc. Twelve response options for each activity are as follows: None, 1-4 minutes (min), 5-19 min, 20-39 min, 40-89 min, 1.5 hours, 2-3 hours, 4-6 hours, 7-10 hours, 11-20 hours, 21-30 hours, 31-40 hours, 40+ hours. The amount of time per week spent on each activity was converted to a hourly scale and the absolute change between baseline and month 12 times were calculated for each participant. The median absolute change in hours per week were compared for each of the 6 activity categories: non-vigorous, moderate, moderate-vigorous, vigorous, and total physical activity and total moderate and vigorous activity combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Average Moderate to Vigorous Physical Activity (MVPA) as Measured by an Ambulatory Accelerometer Assessment (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Metabolic impact for participants in each group from baseline to 12 months was measured by using an ambulatory accelerometer worn by participants around their waist for 7 consecutive days. Participants were required at least 3 days of valid wear time, defined as &gt;= 10 hours of wear per day. The accelerometer measured movement intensity and recorded vertical acceleration as &quot;counts,&quot; providing an indication of the intensity of physical activity associated with locomotion. Non-wear time was identified using Troiano 2007 default settings in the ActiLife v6.13.3 software. The amount of time participants were engaged in moderate to vigorous physical activities (MVPA) was measured by accelerometer as counts per minute (moderate activity = 2020-5998 counts per minute, and vigorous activity = 5999 or more counts per minute). Counts are then transformed into minutes per day with a total range of 0-1440 minutes. The median absolute change in average MVPA was compared between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Bone Density T-score (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The absolute change in bone density t-scores from the baseline to the month 12 assessment for participants in the randomized cohort was measured using bone density at the lumbar spine, bone density at the femoral neck, and bone density at the total hip. A T-score of -1.0 or above is normal bone density. A T-score between -1.0 and -2.5 indicates low bone density or osteopenia. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Serum 25-(OH) Vitamin D (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The absolute change in bone health parameters as measured by the serum 25-(OH) vitamin D level from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Patient Health Questionnaire-9 (PHQ-9) Scores (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The absolute change in scores on the Patient Health Questionnaire-9 (PHQ-9) from baseline after 12 months of study participation for participants was used to measure depression symptoms with a higher number indicating a greater percentage of change in scores. The total Patient Health Questionnaire-9 (PHQ-9) score is calculated by combining the responses of the participant on questions addressing how bothered the participant has been by various problems over the past 2 weeks. Each of the 9 items is scored on a scale of 0 (&quot;Not bothered at all&quot;) to 4 (&quot;Nearly every day&quot;). A total score of 5-9='Mild Depression Symptoms&quot;, 10-4=&quot;Minor Depression, Major Depression (mild), or Dysthymia&quot;, 15-19=&quot;Major Depression, moderately severe&quot;, and &gt;20=&quot;Major Depression&quot;.
Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Attention Function Index (AFI) Scores (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The AFI measures a participants perceived effectiveness in functioning at time of assessment. Each of the 16 items consists of a 100 mm horizontal line anchored with opposite phrases from not at all (0 mm) to extremely well or a great deal (100 mm). Subjects are asked to place a mark on the line that best describes functioning in relation to specific activity. Scores for each item are determined by measuring distance from lower end of scale in millimeters. The total score on the instrument is computed by obtaining an average of 16 scales. The absolute change in score by group from baseline up to month 12 in Attention Function Index was used to measure perceived effectiveness in common activities requiring attention and working memory in daily life with a higher number indicating a greater absolute change in scores. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in the 12-item Short Form Survey (SF-12) Assessment Item Scores for Patients in the Randomized Cohort</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The SF-12 is a 12-item questionnaire used to assess generic health outcomes from the patient's perspective. The SF-12 consists of a subset of 12 items from the SF-36Â® Health Survey (SF-36) and measures two composite outcomes assessing mental health composite score (MCS) and physical health composite scores (PCS). The PCS &amp; MCS are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. The absolute change in item score by group from baseline up to 12 months was used to assess the quality of life/psychosocial impact on the patients with a larger scores indicating a greater degree of change on physical and mental health. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in International Prostate Symptom Score (IPSS) (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The absolute change in score by group from baseline up to month 12 on the International Prostate Symptom Score (IPSS) was used to measure the severity of lower urinary tract symptoms and erectile function with lower numbers indicating less change in symptoms. Seven questions with scores ranging from 1-5 are summed to create a total score. Scores of 1-7 indicate mild symptoms, scores of 8-19 indicate moderate symptoms, and scores of 20-35 indicate severe symptoms. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Last Question on International Prostate Symptom Score (IPSS) (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The absolute change in score by group from baseline up to month 12 on the International Prostate Symptom Score (IPSS) was used to measure the severity of lower urinary tract symptoms and erectile function. The last question on the IPSS can be looked at separately from the total score as it asks the participants to rate the overall quality of life due to their existing urinary symptoms on a scale of 0-6, with lower scores indicating a better quality of life. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Hot Flash Related Daily Interference Scale Score (HFRDIS) (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The absolute change in Hot Flash Related Daily Interference Scale from baseline to month 12 was used to measure the impact of occurrence of hot flashes on daily activities with higher numbers indicating a greater change in the interference of hot flashes with participant's quality of life. The HFRDIS is a 10-item scale measuring the degree hot flashes interfere with nine daily activities; the tenth item measures the degree hot flashes interfere with overall quality of life. The HFRDIS was developed to include daily life activities specific to impact of hot flashes. Participants rate degree to which hot flashes have interfered with each item during previous week using a 0 (do not interfere) to 10 (completely interfere) point scale, with total score ranging from 0-100. Higher scores indicate higher interference and thus, greater impact on quality of life. Women without hot flashes are asked to mark 0 for each item. Group comparisons performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Scores to Assess Erectile and Urinary Function (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The EPIC-26 was measured at baseline and month 12 to determine the impact of quality of life issues across 5 prostate cancer specific domains: Urinary incontinence, Urinary irritation, Bowel function, Sexual function, and Hormonal function and overall total quality of life. Response options for each EPIC item form a Likert scale, and the raw score of each item is then transformed linearly to a 0-100 scale. Multiple items are combined and then averaged to form the domain scores and total score at each time point also ranging from 0-100, with higher scores representing better health related quality of life (HRQOL). Between group comparisons were performed using the Wilcoxon-rank-sum test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Lee Fatigue Scale Scores (Randomized Cohort)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The absolute change in Lee Fatigue Scale from baseline to month 12 was used to measure the impact of Fatigue on a participants quality of life. The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an &quot;X&quot; representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from &quot;not at all tired&quot; to &quot;extremely tired&quot;). Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10). The fatigue subscale score is calculated as the mean of the 13 fatigue items, and the energy subscale score is the mean of the 5 energy items. Higher scores on the fatigue subscale represent greater fatigue severity, and higher scores on the energy subscale indicate higher levels of energy. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (STAND clinic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Dietary Intervention</intervention_name>
    <description>Receive individualized nutrition counseling</description>
    <arm_group_label>Arm II (STAND clinic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Counseling</intervention_name>
    <description>Receive individualized symptom management service counseling</description>
    <arm_group_label>Arm II (STAND clinic)</arm_group_label>
    <other_name>Counseling Intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Educational Intervention</intervention_name>
    <description>Review educational modules</description>
    <arm_group_label>Arm II (STAND clinic)</arm_group_label>
    <other_name>Education for Intervention</other_name>
    <other_name>Intervention by Education</other_name>
    <other_name>Intervention through Education</other_name>
    <other_name>Intervention, Educational</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise Intervention</intervention_name>
    <description>Receive individualized exercise counseling</description>
    <arm_group_label>Arm II (STAND clinic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin Acetate</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (STAND clinic)</arm_group_label>
    <other_name>ZDX</other_name>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (STAND clinic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Given SC or IM</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (STAND clinic)</arm_group_label>
    <other_name>A-43818</other_name>
    <other_name>Abbott 43818</other_name>
    <other_name>Abbott-43818</other_name>
    <other_name>Carcinil</other_name>
    <other_name>Depo-Eligard</other_name>
    <other_name>Eligard</other_name>
    <other_name>Enanton</other_name>
    <other_name>Enantone</other_name>
    <other_name>Enantone-Gyn</other_name>
    <other_name>Ginecrin</other_name>
    <other_name>LEUP</other_name>
    <other_name>Leuplin</other_name>
    <other_name>Leuprorelin Acetate</other_name>
    <other_name>Lucrin</other_name>
    <other_name>Lucrin Depot</other_name>
    <other_name>Lupron</other_name>
    <other_name>Lupron Depot</other_name>
    <other_name>Lupron Depot-3 Month</other_name>
    <other_name>Lupron Depot-4 Month</other_name>
    <other_name>Lupron Depot-Ped</other_name>
    <other_name>Procren</other_name>
    <other_name>Procrin</other_name>
    <other_name>Prostap</other_name>
    <other_name>TAP-144</other_name>
    <other_name>Trenantone</other_name>
    <other_name>Uno-Enantone</other_name>
    <other_name>Viadur</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (STAND clinic)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin Pamoate</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (STAND clinic)</arm_group_label>
    <other_name>Diphereline</other_name>
    <other_name>Pamorelin</other_name>
    <other_name>Trelstar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic confirmation of adenocarcinoma of the prostate

          -  Receiving or planning to receive androgen deprivation therapy (ADT) with luteinizing
             hormone-releasing hormone (LHRH) agonist or antagonist

          -  Expected duration of ADT at least 12 months from date of study consent

          -  Concurrent antiandrogen therapy allowed but not required

          -  First dose of LHRH agonist or antagonist no more than 6 months prior to date of study
             content

          -  Prior/concurrent radiation allowed

          -  Other investigational agents in addition to LHRH agonist/antagonist are allowed (e.g.
             novel anti-androgens, androgen synthesis inhibitors)

          -  Prior androgen deprivation therapy allowed, provided there is documented evidence of
             testosterone recovery to &gt; 150 ng/dL and greater than 12 months duration between last
             ?effective? date of ADT and date of study consent

          -  Randomized cohort only:

               -  No prior chemotherapy within 12 months of start date of study

               -  No planned chemotherapy at least 12 months from study entry

          -  Non-randomized pilot cohort:

               -  Concurrent chemotherapy (initiated within 3 months of study entry) or planned
                  chemotherapy within 3 months of study entry

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 ? 2

          -  Ability to sign written informed consent

          -  Willing to attend monthly clinic visits at University of California, San Francisco
             (UCSF)

        Exclusion Criteria:

          -  Physically unable or unwilling to participate in recommended exercise programs or
             travel to UCSF on a monthly basis

          -  Presence of permanent pacemaker or implantable medical device

               -  Artificial joint prostheses and venous filters are allowed
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rahul Aggarwal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 15, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <results_first_submitted>November 20, 2019</results_first_submitted>
  <results_first_submitted_qc>May 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2020</results_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 7, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT02168062/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT02168062/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study included a small, non-randomized pilot cohort of 8 patients receiving concurrent chemohormonal therapy who were enrolled in parallel to assess the feasibility of STAND clinic participation in this patient population but were not included in the final group comparisons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Standard of Care)</title>
          <description>Patients receive leuprolide acetate subcutaneous (SC) or intramuscular (IM), or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (STAND Clinic)</title>
          <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
        <group group_id="P3">
          <title>Non-Randomized Pilot Cohort</title>
          <description>A non-randomized pilot cohort receiving concurrent chemohormonal therapy will be enrolled in parallel to assess the feasibility of STAND clinic participation in this patient population.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Standard of Care)</title>
          <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
        </group>
        <group group_id="B2">
          <title>Arm II (STAND Clinic)</title>
          <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
        </group>
        <group group_id="B3">
          <title>Non-Randomized Pilot Cohort</title>
          <description>A non-randomized pilot cohort of 20 patients receiving concurrent chemohormonal therapy will be enrolled in parallel to assess the feasibility of STAND clinic participation in this patient population.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>50-60 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61-70 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>71-80 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>81-90 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in Percentage Body Fat Mass as Measured by Bioelectrical Impedance Analyzer (Randomized Cohort)</title>
        <description>The absolute change from baseline in percentage body fat after 12 months of study participation for participants in the randomized cohort was measured using a bioelectrical impedance analyzer and between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Percentage Body Fat Mass as Measured by Bioelectrical Impedance Analyzer (Randomized Cohort)</title>
          <description>The absolute change from baseline in percentage body fat after 12 months of study participation for participants in the randomized cohort was measured using a bioelectrical impedance analyzer and between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>percentage of body fat mass</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-28.5" upper_limit="11.6"/>
                    <measurement group_id="O2" value="6.8" lower_limit="-20.2" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in the Non-randomized, Pilot, Cohort Who Completed Clinic Visits</title>
        <description>The percentage of participants in the pilot, non-randomized cohort who completed clinic visits for Supportive Therapy in Androgen Deprivation (STAND) will be reported to assess feasibility.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Randomized Pilot Cohort</title>
            <description>A non-randomized pilot cohort receiving concurrent chemohormonal therapy will be enrolled in parallel to assess the feasibility of STAND clinic participation in this patient population.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in the Non-randomized, Pilot, Cohort Who Completed Clinic Visits</title>
          <description>The percentage of participants in the pilot, non-randomized cohort who completed clinic visits for Supportive Therapy in Androgen Deprivation (STAND) will be reported to assess feasibility.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Blood Pressure (Randomized Cohort)</title>
        <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in systolic and diastolic blood pressure from the baseline to month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Blood Pressure (Randomized Cohort)</title>
          <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in systolic and diastolic blood pressure from the baseline to month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="-11" upper_limit="46"/>
                    <measurement group_id="O2" value="9" lower_limit="-25" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-10" upper_limit="37"/>
                    <measurement group_id="O2" value="-3" lower_limit="-16" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Systolic Blood Pressure measurement comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diastolic Blood Pressure measurement comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Body Weight (Randomized Cohort)</title>
        <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in body weight from the baseline to month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Body Weight (Randomized Cohort)</title>
          <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in body weight from the baseline to month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-8.4" upper_limit="15"/>
                    <measurement group_id="O2" value="2.6" lower_limit="-11.3" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weight measurement comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Percentage of Body Fat (Randomized Cohort)</title>
        <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in percentage of body fat from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Percentage of Body Fat (Randomized Cohort)</title>
          <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in percentage of body fat from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>percentage of body fat</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-28.5" upper_limit="11.6"/>
                    <measurement group_id="O2" value="6.8" lower_limit="-20.2" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage body fat measurement comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Waist Circumference (Randomized Cohort)</title>
        <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in waist circumference from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Waist Circumference (Randomized Cohort)</title>
          <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in waist circumference from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="-8" upper_limit="14"/>
                    <measurement group_id="O2" value="1.7" lower_limit="-4" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Waist measurement comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Hemoglobin A1c (Randomized Cohort)</title>
        <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in percentage hemoglobin A1c from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Hemoglobin A1c (Randomized Cohort)</title>
          <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in percentage hemoglobin A1c from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.8" upper_limit="0.7"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.8" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hemoglobin A1C measurement comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Insulin Resistance Score (Randomized Cohort)</title>
        <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in insulin resistance scores from the baseline to the month 12 assessment. Insulin resistance scores were calculated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). This calculation marks for both the presence and extent of any insulin resistance that participants might currently express. The HOMA-IR is an assessment using insulin and glucose lab values to generate an insulin resistance score. A healthy score range is 1.0 (0.5-1.4). A score of less than 1.0 means you are insulin-sensitive which is optimal. A score above 1.9 indicates early insulin resistance. A score above 2.9 indicates significant insulin resistance. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Insulin Resistance Score (Randomized Cohort)</title>
          <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in insulin resistance scores from the baseline to the month 12 assessment. Insulin resistance scores were calculated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). This calculation marks for both the presence and extent of any insulin resistance that participants might currently express. The HOMA-IR is an assessment using insulin and glucose lab values to generate an insulin resistance score. A healthy score range is 1.0 (0.5-1.4). A score of less than 1.0 means you are insulin-sensitive which is optimal. A score above 1.9 indicates early insulin resistance. A score above 2.9 indicates significant insulin resistance. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1.5" upper_limit="5.4"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-3.1" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Insulin resistance score comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Fasting Lipids (Randomized Cohort)</title>
        <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in fasting lipids which includes total cholesterol, low density lipoprotein, High density lipoprotein, and triglycerides levels from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Fasting Lipids (Randomized Cohort)</title>
          <description>Metabolic and cardiac impact for participants in the randomized cohort was measured by calculating the absolute change in fasting lipids which includes total cholesterol, low density lipoprotein, High density lipoprotein, and triglycerides levels from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>milligram per deciliter (mg/dL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-313" upper_limit="134"/>
                    <measurement group_id="O2" value="-1" lower_limit="-102" upper_limit="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low density lipoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" lower_limit="-26" upper_limit="86"/>
                    <measurement group_id="O2" value="-4" lower_limit="-64" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High density lipoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="-18" upper_limit="46"/>
                    <measurement group_id="O2" value="7" lower_limit="-70.4" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="-79" upper_limit="188"/>
                    <measurement group_id="O2" value="-3" lower_limit="-135" upper_limit="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol measurement comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total low density lipid measurement comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total high density lipid measurement comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total triglyceride measurement comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Hours Per Week of Physical Activity Category as Measured by the Exercise Pattern Assessment (Randomized Cohort)</title>
        <description>Metabolic impact for participants from baseline to 12 months was measured using an exercise pattern questionnaire. The questionnaire measured self-reported average total time per week over the past year the participant participated in various physical activities such as walking, tennis, yoga, swimming, etc. Twelve response options for each activity are as follows: None, 1-4 minutes (min), 5-19 min, 20-39 min, 40-89 min, 1.5 hours, 2-3 hours, 4-6 hours, 7-10 hours, 11-20 hours, 21-30 hours, 31-40 hours, 40+ hours. The amount of time per week spent on each activity was converted to a hourly scale and the absolute change between baseline and month 12 times were calculated for each participant. The median absolute change in hours per week were compared for each of the 6 activity categories: non-vigorous, moderate, moderate-vigorous, vigorous, and total physical activity and total moderate and vigorous activity combined.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Only a small subset of patients reported both baseline and 12 month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Hours Per Week of Physical Activity Category as Measured by the Exercise Pattern Assessment (Randomized Cohort)</title>
          <description>Metabolic impact for participants from baseline to 12 months was measured using an exercise pattern questionnaire. The questionnaire measured self-reported average total time per week over the past year the participant participated in various physical activities such as walking, tennis, yoga, swimming, etc. Twelve response options for each activity are as follows: None, 1-4 minutes (min), 5-19 min, 20-39 min, 40-89 min, 1.5 hours, 2-3 hours, 4-6 hours, 7-10 hours, 11-20 hours, 21-30 hours, 31-40 hours, 40+ hours. The amount of time per week spent on each activity was converted to a hourly scale and the absolute change between baseline and month 12 times were calculated for each participant. The median absolute change in hours per week were compared for each of the 6 activity categories: non-vigorous, moderate, moderate-vigorous, vigorous, and total physical activity and total moderate and vigorous activity combined.</description>
          <population>Only a small subset of patients reported both baseline and 12 month data.</population>
          <units>hours per week</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-vigorous physical activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" lower_limit="-10.00" upper_limit="6.54"/>
                    <measurement group_id="O2" value="-1.03" lower_limit="-7.30" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate physical activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-7.00" upper_limit="7.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-8.50" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vigorous physical activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" lower_limit="-26.22" upper_limit="37.46"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-5.00" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total physical activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.30" lower_limit="-19.68" upper_limit="39.26"/>
                    <measurement group_id="O2" value="-.90" lower_limit="-6.58" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Moderate-Vigorous physical activity (MVPA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-19.22" upper_limit="39.46"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-5.54" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-vigorous physical activity comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate physical activity comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.979</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate-Vigorous physical activity comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.884</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vigorous physical activity comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.678</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total physical activity comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.464</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Average Moderate to Vigorous Physical Activity (MVPA) as Measured by an Ambulatory Accelerometer Assessment (Randomized Cohort)</title>
        <description>Metabolic impact for participants in each group from baseline to 12 months was measured by using an ambulatory accelerometer worn by participants around their waist for 7 consecutive days. Participants were required at least 3 days of valid wear time, defined as &gt;= 10 hours of wear per day. The accelerometer measured movement intensity and recorded vertical acceleration as &quot;counts,&quot; providing an indication of the intensity of physical activity associated with locomotion. Non-wear time was identified using Troiano 2007 default settings in the ActiLife v6.13.3 software. The amount of time participants were engaged in moderate to vigorous physical activities (MVPA) was measured by accelerometer as counts per minute (moderate activity = 2020-5998 counts per minute, and vigorous activity = 5999 or more counts per minute). Counts are then transformed into minutes per day with a total range of 0-1440 minutes. The median absolute change in average MVPA was compared between the two groups.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Only a small subset of patients reported both baseline and 12 month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Average Moderate to Vigorous Physical Activity (MVPA) as Measured by an Ambulatory Accelerometer Assessment (Randomized Cohort)</title>
          <description>Metabolic impact for participants in each group from baseline to 12 months was measured by using an ambulatory accelerometer worn by participants around their waist for 7 consecutive days. Participants were required at least 3 days of valid wear time, defined as &gt;= 10 hours of wear per day. The accelerometer measured movement intensity and recorded vertical acceleration as &quot;counts,&quot; providing an indication of the intensity of physical activity associated with locomotion. Non-wear time was identified using Troiano 2007 default settings in the ActiLife v6.13.3 software. The amount of time participants were engaged in moderate to vigorous physical activities (MVPA) was measured by accelerometer as counts per minute (moderate activity = 2020-5998 counts per minute, and vigorous activity = 5999 or more counts per minute). Counts are then transformed into minutes per day with a total range of 0-1440 minutes. The median absolute change in average MVPA was compared between the two groups.</description>
          <population>Only a small subset of patients reported both baseline and 12 month data.</population>
          <units>minutes per day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.40" lower_limit="-45.46" upper_limit="39.50"/>
                    <measurement group_id="O2" value="-2.36" lower_limit="-26.30" upper_limit="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Average MVPA Minutes per Day Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.838</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Bone Density T-score (Randomized Cohort)</title>
        <description>The absolute change in bone density t-scores from the baseline to the month 12 assessment for participants in the randomized cohort was measured using bone density at the lumbar spine, bone density at the femoral neck, and bone density at the total hip. A T-score of -1.0 or above is normal bone density. A T-score between -1.0 and -2.5 indicates low bone density or osteopenia. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Bone Density T-score (Randomized Cohort)</title>
          <description>The absolute change in bone density t-scores from the baseline to the month 12 assessment for participants in the randomized cohort was measured using bone density at the lumbar spine, bone density at the femoral neck, and bone density at the total hip. A T-score of -1.0 or above is normal bone density. A T-score between -1.0 and -2.5 indicates low bone density or osteopenia. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>t-score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bone density at the lumbar spine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-3.50" upper_limit="0.10"/>
                    <measurement group_id="O2" value="-0.40" lower_limit="-1.80" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone density at the femoral neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-2.30" upper_limit="1.90"/>
                    <measurement group_id="O2" value="-0.20" lower_limit="-2.10" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone density of total hip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" lower_limit="-2.30" upper_limit="0.10"/>
                    <measurement group_id="O2" value="-0.10" lower_limit="-0.70" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bone Density at the lumbar spine comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.677</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bone Density at the femoral neck comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.493</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bone Density of the total hip comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.807</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Serum 25-(OH) Vitamin D (Randomized Cohort)</title>
        <description>The absolute change in bone health parameters as measured by the serum 25-(OH) vitamin D level from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Serum 25-(OH) Vitamin D (Randomized Cohort)</title>
          <description>The absolute change in bone health parameters as measured by the serum 25-(OH) vitamin D level from the baseline to the month 12 assessment. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" lower_limit="-14" upper_limit="24"/>
                    <measurement group_id="O2" value="8.10" lower_limit="-21" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum 25-(OH) vitamin D level comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.403</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Patient Health Questionnaire-9 (PHQ-9) Scores (Randomized Cohort)</title>
        <description>The absolute change in scores on the Patient Health Questionnaire-9 (PHQ-9) from baseline after 12 months of study participation for participants was used to measure depression symptoms with a higher number indicating a greater percentage of change in scores. The total Patient Health Questionnaire-9 (PHQ-9) score is calculated by combining the responses of the participant on questions addressing how bothered the participant has been by various problems over the past 2 weeks. Each of the 9 items is scored on a scale of 0 (&quot;Not bothered at all&quot;) to 4 (&quot;Nearly every day&quot;). A total score of 5-9='Mild Depression Symptoms&quot;, 10-4=&quot;Minor Depression, Major Depression (mild), or Dysthymia&quot;, 15-19=&quot;Major Depression, moderately severe&quot;, and &gt;20=&quot;Major Depression&quot;.
Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Patient Health Questionnaire-9 (PHQ-9) Scores (Randomized Cohort)</title>
          <description>The absolute change in scores on the Patient Health Questionnaire-9 (PHQ-9) from baseline after 12 months of study participation for participants was used to measure depression symptoms with a higher number indicating a greater percentage of change in scores. The total Patient Health Questionnaire-9 (PHQ-9) score is calculated by combining the responses of the participant on questions addressing how bothered the participant has been by various problems over the past 2 weeks. Each of the 9 items is scored on a scale of 0 (&quot;Not bothered at all&quot;) to 4 (&quot;Nearly every day&quot;). A total score of 5-9='Mild Depression Symptoms&quot;, 10-4=&quot;Minor Depression, Major Depression (mild), or Dysthymia&quot;, 15-19=&quot;Major Depression, moderately severe&quot;, and &gt;20=&quot;Major Depression&quot;.
Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-5.0" upper_limit="3.00"/>
                    <measurement group_id="O2" value=".50" lower_limit="-5.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.385</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Attention Function Index (AFI) Scores (Randomized Cohort)</title>
        <description>The AFI measures a participants perceived effectiveness in functioning at time of assessment. Each of the 16 items consists of a 100 mm horizontal line anchored with opposite phrases from not at all (0 mm) to extremely well or a great deal (100 mm). Subjects are asked to place a mark on the line that best describes functioning in relation to specific activity. Scores for each item are determined by measuring distance from lower end of scale in millimeters. The total score on the instrument is computed by obtaining an average of 16 scales. The absolute change in score by group from baseline up to month 12 in Attention Function Index was used to measure perceived effectiveness in common activities requiring attention and working memory in daily life with a higher number indicating a greater absolute change in scores. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Only a subset of patients reported both baseline and 12 month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Attention Function Index (AFI) Scores (Randomized Cohort)</title>
          <description>The AFI measures a participants perceived effectiveness in functioning at time of assessment. Each of the 16 items consists of a 100 mm horizontal line anchored with opposite phrases from not at all (0 mm) to extremely well or a great deal (100 mm). Subjects are asked to place a mark on the line that best describes functioning in relation to specific activity. Scores for each item are determined by measuring distance from lower end of scale in millimeters. The total score on the instrument is computed by obtaining an average of 16 scales. The absolute change in score by group from baseline up to month 12 in Attention Function Index was used to measure perceived effectiveness in common activities requiring attention and working memory in daily life with a higher number indicating a greater absolute change in scores. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <population>Only a subset of patients reported both baseline and 12 month data.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="-27.75" upper_limit="26.62"/>
                    <measurement group_id="O2" value="-4" lower_limit="-15.26" upper_limit="10.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Attention Function Index (AFI) Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.148</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in the 12-item Short Form Survey (SF-12) Assessment Item Scores for Patients in the Randomized Cohort</title>
        <description>The SF-12 is a 12-item questionnaire used to assess generic health outcomes from the patient's perspective. The SF-12 consists of a subset of 12 items from the SF-36Â® Health Survey (SF-36) and measures two composite outcomes assessing mental health composite score (MCS) and physical health composite scores (PCS). The PCS &amp; MCS are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. The absolute change in item score by group from baseline up to 12 months was used to assess the quality of life/psychosocial impact on the patients with a larger scores indicating a greater degree of change on physical and mental health. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Only a subset of participants completed questionnaires at both baseline and 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in the 12-item Short Form Survey (SF-12) Assessment Item Scores for Patients in the Randomized Cohort</title>
          <description>The SF-12 is a 12-item questionnaire used to assess generic health outcomes from the patient's perspective. The SF-12 consists of a subset of 12 items from the SF-36Â® Health Survey (SF-36) and measures two composite outcomes assessing mental health composite score (MCS) and physical health composite scores (PCS). The PCS &amp; MCS are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. The absolute change in item score by group from baseline up to 12 months was used to assess the quality of life/psychosocial impact on the patients with a larger scores indicating a greater degree of change on physical and mental health. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <population>Only a subset of participants completed questionnaires at both baseline and 12 months.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental Composite Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" lower_limit="-8.46" upper_limit="11.90"/>
                    <measurement group_id="O2" value="-2.37" lower_limit="-7.37" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Composite Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.90" lower_limit="-17.82" upper_limit="18.75"/>
                    <measurement group_id="O2" value="-1.60" lower_limit="-6.65" upper_limit="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Composite Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.077</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Composite Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.401</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in International Prostate Symptom Score (IPSS) (Randomized Cohort)</title>
        <description>The absolute change in score by group from baseline up to month 12 on the International Prostate Symptom Score (IPSS) was used to measure the severity of lower urinary tract symptoms and erectile function with lower numbers indicating less change in symptoms. Seven questions with scores ranging from 1-5 are summed to create a total score. Scores of 1-7 indicate mild symptoms, scores of 8-19 indicate moderate symptoms, and scores of 20-35 indicate severe symptoms. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in International Prostate Symptom Score (IPSS) (Randomized Cohort)</title>
          <description>The absolute change in score by group from baseline up to month 12 on the International Prostate Symptom Score (IPSS) was used to measure the severity of lower urinary tract symptoms and erectile function with lower numbers indicating less change in symptoms. Seven questions with scores ranging from 1-5 are summed to create a total score. Scores of 1-7 indicate mild symptoms, scores of 8-19 indicate moderate symptoms, and scores of 20-35 indicate severe symptoms. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-20" upper_limit="24"/>
                    <measurement group_id="O2" value="-2" lower_limit="-9" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Last Question on International Prostate Symptom Score (IPSS) (Randomized Cohort)</title>
        <description>The absolute change in score by group from baseline up to month 12 on the International Prostate Symptom Score (IPSS) was used to measure the severity of lower urinary tract symptoms and erectile function. The last question on the IPSS can be looked at separately from the total score as it asks the participants to rate the overall quality of life due to their existing urinary symptoms on a scale of 0-6, with lower scores indicating a better quality of life. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Last Question on International Prostate Symptom Score (IPSS) (Randomized Cohort)</title>
          <description>The absolute change in score by group from baseline up to month 12 on the International Prostate Symptom Score (IPSS) was used to measure the severity of lower urinary tract symptoms and erectile function. The last question on the IPSS can be looked at separately from the total score as it asks the participants to rate the overall quality of life due to their existing urinary symptoms on a scale of 0-6, with lower scores indicating a better quality of life. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-3" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="-1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.676</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Hot Flash Related Daily Interference Scale Score (HFRDIS) (Randomized Cohort)</title>
        <description>The absolute change in Hot Flash Related Daily Interference Scale from baseline to month 12 was used to measure the impact of occurrence of hot flashes on daily activities with higher numbers indicating a greater change in the interference of hot flashes with participant's quality of life. The HFRDIS is a 10-item scale measuring the degree hot flashes interfere with nine daily activities; the tenth item measures the degree hot flashes interfere with overall quality of life. The HFRDIS was developed to include daily life activities specific to impact of hot flashes. Participants rate degree to which hot flashes have interfered with each item during previous week using a 0 (do not interfere) to 10 (completely interfere) point scale, with total score ranging from 0-100. Higher scores indicate higher interference and thus, greater impact on quality of life. Women without hot flashes are asked to mark 0 for each item. Group comparisons performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Hot Flash Related Daily Interference Scale Score (HFRDIS) (Randomized Cohort)</title>
          <description>The absolute change in Hot Flash Related Daily Interference Scale from baseline to month 12 was used to measure the impact of occurrence of hot flashes on daily activities with higher numbers indicating a greater change in the interference of hot flashes with participant's quality of life. The HFRDIS is a 10-item scale measuring the degree hot flashes interfere with nine daily activities; the tenth item measures the degree hot flashes interfere with overall quality of life. The HFRDIS was developed to include daily life activities specific to impact of hot flashes. Participants rate degree to which hot flashes have interfered with each item during previous week using a 0 (do not interfere) to 10 (completely interfere) point scale, with total score ranging from 0-100. Higher scores indicate higher interference and thus, greater impact on quality of life. Women without hot flashes are asked to mark 0 for each item. Group comparisons performed using the Wilcoxon-rank-sum test.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="-22" upper_limit="67"/>
                    <measurement group_id="O2" value="4.5" lower_limit="-52" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.183</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Scores to Assess Erectile and Urinary Function (Randomized Cohort)</title>
        <description>The EPIC-26 was measured at baseline and month 12 to determine the impact of quality of life issues across 5 prostate cancer specific domains: Urinary incontinence, Urinary irritation, Bowel function, Sexual function, and Hormonal function and overall total quality of life. Response options for each EPIC item form a Likert scale, and the raw score of each item is then transformed linearly to a 0-100 scale. Multiple items are combined and then averaged to form the domain scores and total score at each time point also ranging from 0-100, with higher scores representing better health related quality of life (HRQOL). Between group comparisons were performed using the Wilcoxon-rank-sum test</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Only a subset of patients reported both baseline and 12 month data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC, and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, or goserelin acetate SC every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietitian, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Scores to Assess Erectile and Urinary Function (Randomized Cohort)</title>
          <description>The EPIC-26 was measured at baseline and month 12 to determine the impact of quality of life issues across 5 prostate cancer specific domains: Urinary incontinence, Urinary irritation, Bowel function, Sexual function, and Hormonal function and overall total quality of life. Response options for each EPIC item form a Likert scale, and the raw score of each item is then transformed linearly to a 0-100 scale. Multiple items are combined and then averaged to form the domain scores and total score at each time point also ranging from 0-100, with higher scores representing better health related quality of life (HRQOL). Between group comparisons were performed using the Wilcoxon-rank-sum test</description>
          <population>Only a subset of patients reported both baseline and 12 month data.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.91" lower_limit="-25.53" upper_limit="17.10"/>
                    <measurement group_id="O2" value="-3.85" lower_limit="-11.54" upper_limit="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-37.75" upper_limit="39.50"/>
                    <measurement group_id="O2" value="0" lower_limit="-20.57" upper_limit="17.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.00" lower_limit="-27.50" upper_limit="60.00"/>
                    <measurement group_id="O2" value="5.00" lower_limit="-5.00" upper_limit="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-87.50" upper_limit="25.00"/>
                    <measurement group_id="O2" value="-4.17" lower_limit="-16.67" upper_limit="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.50" lower_limit="-47.00" upper_limit="16.67"/>
                    <measurement group_id="O2" value="-2.08" lower_limit="-48.67" upper_limit="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hormonal Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-41.25" upper_limit="12.50"/>
                    <measurement group_id="O2" value="-17.50" lower_limit="-35.00" upper_limit="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>EPIC-26 Total Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>EPIC-26 Urinary Incontinence Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.844</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>EPIC-26 Urinary Irriation Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>EPIC-26 Bowel Function Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.472</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>EPIC-26 Sexual Function Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.405</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>EPIC-26 Hormonal Function Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.749</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Lee Fatigue Scale Scores (Randomized Cohort)</title>
        <description>The absolute change in Lee Fatigue Scale from baseline to month 12 was used to measure the impact of Fatigue on a participants quality of life. The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an &quot;X&quot; representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from &quot;not at all tired&quot; to &quot;extremely tired&quot;). Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10). The fatigue subscale score is calculated as the mean of the 13 fatigue items, and the energy subscale score is the mean of the 5 energy items. Higher scores on the fatigue subscale represent greater fatigue severity, and higher scores on the energy subscale indicate higher levels of energy. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Standard of Care)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
          <group group_id="O2">
            <title>Arm II (STAND Clinic)</title>
            <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Lee Fatigue Scale Scores (Randomized Cohort)</title>
          <description>The absolute change in Lee Fatigue Scale from baseline to month 12 was used to measure the impact of Fatigue on a participants quality of life. The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an &quot;X&quot; representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from &quot;not at all tired&quot; to &quot;extremely tired&quot;). Each line is 100 mm in length - thus, scores fall between 0 and 100. The instrument also possesses two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10). The fatigue subscale score is calculated as the mean of the 13 fatigue items, and the energy subscale score is the mean of the 5 energy items. Higher scores on the fatigue subscale represent greater fatigue severity, and higher scores on the energy subscale indicate higher levels of energy. Between group comparisons were performed using the Wilcoxon-rank-sum test.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" lower_limit="-36.09" upper_limit="33.38"/>
                    <measurement group_id="O2" value="3.15" lower_limit="-5.40" upper_limit="29.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" lower_limit="-19.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="1.30" lower_limit="-15.60" upper_limit="27.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fatigue Scale Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.907</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Energy Scale Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.792</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 months</time_frame>
      <desc>The Behavioral-Dietary intervention under investigation was not determined to pose any significant risk to the patient however, all grade(s) 3-5 adverse events, whether or not unexpected, and whether or not considered to be associated with the use of the study treatment were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Standard of Care)</title>
          <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
        </group>
        <group group_id="E2">
          <title>Arm II (STAND Clinic)</title>
          <description>Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
Behavioral Dietary Intervention: Receive individualized nutrition counseling
Counseling: Receive individualized symptom management service counseling
Educational Intervention: Review educational modules
Exercise Intervention: Receive individualized exercise counseling
Goserelin Acetate: Given SC
Laboratory Biomarker Analysis: Correlative studies
Leuprolide Acetate: Given SC or IM
Quality-of-Life Assessment: Ancillary studies
Triptorelin Pamoate: Given IM</description>
        </group>
        <group group_id="E3">
          <title>Non-Randomized Pilot Cohort</title>
          <description>A non-randomized pilot cohort receiving concurrent chemohormonal therapy will be enrolled in parallel to assess the feasibility of STAND clinic participation in this patient population.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Absolute change calculated for outcomes and and non-parametric statistical tests performed due to small sample size from early study termination. Non-randomized pilot cohort to assess feasibility was not included in group comparisons.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Li Zhang, PhD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 476-5339</phone>
      <email>Li.Zhang@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

